FdaApplication
NDA 220305
Identifiers
- fda_app_no: NDA220305
Properties
| Property | Value |
|---|---|
| applicant_name | KURA ONCOLOGY INC |
| application_type | NDA |
| approval_date | 2025-11-13 |
Revenue by product
KOMZIFTI
| Period | Revenue |
|---|---|
| Q2 2026 | $9.1M |
| Q1 2026 | $5.8M |
| Q3 2025 | $20.8M† |
| Q2 2025 | $15.3M† |
| Q1 2025 | $14.1M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| KOMZIFTI | ZIFTOMENIB | 200MG | CAPSULE;ORAL |
1 product